Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial

BACKGROUND: Mass azithromycin administration has been used to reduce under-five mortality in sub-Saharan Africa, but concerns remain about its potential impact on antimicrobial resistance (AMR). METHODS AND FINDINGS: The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regiments with Azithromycin (LAKANA) trial was a cluster-randomized, placebo-controlled trial conducted in Mali, enrolling infants aged 1-11 months randomized to placebo, twice-yearly azithromycin, or quarterly azithromycin for 2 years. The trial did not find any mortality benefit amongst treated children. The current analysis is a sub-study of the parent trial examining AMR outcomes. Repeated cross-sectional nasopharyngeal and rectal swabs were collected from children aged 4-14-months in villages randomized to placebo, twice-yearly or quarterly azithromycin, and from untreated contacts aged 49-59-months at baseline, 12-, 24-, and 36-months post-village enrollment across 59 LAKANA trial villages. Phenotypic resistance to macrolide and nonmacrolide antibiotics was assessed in Streptococcus pneumoniae (S. pneumoniae) and Escherichia coli (E. coli) isolates using disk diffusion or E-tests. The primary noninferiority analysis evaluated macrolide resistance prevalence at 36-months among younger children and at 24-months among older contacts, with predefined margin of +10 percentage points. A total of 5,025 nasopharyngeal and 5,021 rectal samples were analyzed. At baseline, among 4-14-month-old children, macrolide resistance in S. pneumoniae was 16.6%, 15.5%, and 11.1% in the placebo, twice-yearly and quarterly azithromycin groups, respectively, and 5.0%, 5.0%, and 0.0% in E. coli. At 36-months, corresponding prevalences were 13.4%, 14.5%, and 17.2% for S. pneumoniae, and 5.1%, 6.4%, and 9.1% for E. coli. The difference between placebo and twice-yearly groups was 1.0% (95% CI [-4.7, 6.8]) for S. pneumoniae and 1.3% (95% CI [-2.4, 4.9]) for E. coli; corresponding differences for quarterly azithromycin group was 3.8% (95% CI [-3.3, 10.9]) for S. pneumoniae and 4.0% (95% CI [-0.7, 8.7]) for E. coli. Among untreated older children, there were no marked inter-group differences in macrolide resistance either at baseline or at 24-months. The study may not have been large enough to detect a small increase in macrolide resistance in S. pneumoniae among young children in villages that received quarterly azithromycin. CONCLUSIONS: Twice-yearly azithromycin administration to 1-11-month-old infants for 2 years in Mali did not increase macrolide resistance in treated children or untreated contacts and met the predefined noninferiority margin in tested isolates. Quarterly administration, however, cannot exclude a modest dose-dependent increase of macrolide resistance in S. pneumoniae and E. coli.

Authors

Institutions

Publication Details

Journal
PLoS Medicine
Published
2026-11-13
DOI
https://doi.org/10.1371/journal.pmed.1005296
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial

Yin Bun Cheung, Per Ashorn, Ulla Ashorn, Nigel Jonathan Klein et al.
4 links
PLoS Medicine
Antibiotic Use and Resistance
article

Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial

Yin Bun Cheung, Per Ashorn, Ulla Ashorn, Nigel Jonathan Klein, Rikhard Ihamuotila, Juho Luoma, Tiia Haapaniemi, Elaine Cloutman-Green, Fadima Cheick Haidara, Samba Ousmane Sow, Yue‐Mei Fan, Owen Martell, Camilla Ducker, Dagmar Alber, Laura Adubra, Aminata Sangaré, Oumar Samaké, Jane Juma, Kaisa Ylikruuvi, Oumou Bouare, Awa Traore
article en

Abstract

BACKGROUND: Mass azithromycin administration has been used to reduce under-five mortality in sub-Saharan Africa, but concerns remain about its potential impact on antimicrobial resistance (AMR). METHODS AND FINDINGS: The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regiments with Azithromycin (LAKANA) trial was a cluster-randomized, placebo-controlled trial conducted in Mali, enrolling infants aged 1-11 months randomized to placebo, twice-yearly azithromycin, or quarterly azithromycin for 2 years. The trial did not find any mortality benefit amongst treated children. The current analysis is a sub-study of the parent trial examining AMR outcomes. Repeated cross-sectional nasopharyngeal and rectal swabs were collected from children aged 4-14-months in villages randomized to placebo, twice-yearly or quarterly azithromycin, and from untreated contacts aged 49-59-months at baseline, 12-, 24-, and 36-months post-village enrollment across 59 LAKANA trial villages. Phenotypic resistance to macrolide and nonmacrolide antibiotics was assessed in Streptococcus pneumoniae (S. pneumoniae) and Escherichia coli (E. coli) isolates using disk diffusion or E-tests. The primary noninferiority analysis evaluated macrolide resistance prevalence at 36-months among younger children and at 24-months among older contacts, with predefined margin of +10 percentage points. A total of 5,025 nasopharyngeal and 5,021 rectal samples were analyzed. At baseline, among 4-14-month-old children, macrolide resistance in S. pneumoniae was 16.6%, 15.5%, and 11.1% in the placebo, twice-yearly and quarterly azithromycin groups, respectively, and 5.0%, 5.0%, and 0.0% in E. coli. At 36-months, corresponding prevalences were 13.4%, 14.5%, and 17.2% for S. pneumoniae, and 5.1%, 6.4%, and 9.1% for E. coli. The difference between placebo and twice-yearly groups was 1.0% (95% CI [-4.7, 6.8]) for S. pneumoniae and 1.3% (95% CI [-2.4, 4.9]) for E. coli; corresponding differences for quarterly azithromycin group was 3.8% (95% CI [-3.3, 10.9]) for S. pneumoniae and 4.0% (95% CI [-0.7, 8.7]) for E. coli. Among untreated older children, there were no marked inter-group differences in macrolide resistance either at baseline or at 24-months. The study may not have been large enough to detect a small increase in macrolide resistance in S. pneumoniae among young children in villages that received quarterly azithromycin. CONCLUSIONS: Twice-yearly azithromycin administration to 1-11-month-old infants for 2 years in Mali did not increase macrolide resistance in treated children or untreated contacts and met the predefined noninferiority margin in tested isolates. Quarterly administration, however, cannot exclude a modest dose-dependent increase of macrolide resistance in S. pneumoniae and E. coli.

PLoS MedicineVol. 23(11)
Tampere University (FI), Great Ormond Street Hospital (GB), Centre Pour le Développement des Vaccins-Mali (ML), Tampere University Hospital (FI), University of Tampere (FI), University College London (GB)
Bill and Melinda Gates Foundation, Pfizer
Good health and well-being
Antibiotic Use and Resistance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon